Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6989980 | 0.72 | KDM4E (0.43) | KDM4ECA12USP2CA1CA2 | |
| SCHEMBL25716769 | 0.72 | KDM4E (0.43) | KDM4ECA12USP2CA1CA2 | |
| SCHEMBL18535393 | 0.69 | GPR3 (0.59) | KDM4ECA12USP2CA1CA2 | |
| SCHEMBL10860632 | 0.68 | GPR3 (0.46) | KDM4ECA12USP2CA1CA2 | |
| SCHEMBL13403041 | 0.65 | KDM4E (0.53) | KDM4ECA12USP2CA1CA2 | |
| Saccharin SCHEMBL28045129 | 0.65 | CA12 (0.92) | KDM4ECA12USP2CA1CA2 | |
| Saccharin SCHEMBL29037506 | 0.65 | CA12 (0.92) | KDM4ECA12USP2CA1CA2 | |
| Saccharin SCHEMBL8565204 | 0.64 | CA12 (0.79) | KDM4ECA12USP2CA1CA2 | |
| Saccharin SCHEMBL23581470 | 0.64 | CA12 (0.88) | KDM4ECA12USP2CA1CA2 | |
| SCHEMBL27047101 | 0.64 | KDM4E (0.57) | KDM4ECA12USP2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241922-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) | 2025-07-31 | — | — | US | claimed |
| US-20240197741-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA(SHANGHAI)CO., LTD. (CN) | 2024-06-20 | — | — | US | claimed |
| CN-117355527-B | Anti-inflammatory coupling compound medicine and preparation method and application thereof | 上海椿安生物医药科技有限公司 | 2024-06-07 | — | — | CN | claimed |
| EP-4357346-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Coval Biopharma (Shanghai) Co., Ltd. (CN) | 2024-04-24 | — | — | EP | claimed |
| CN-117355527-A | External anti-inflammatory coupling compound medicine and preparation method and application thereof | 上海椿安生物医药科技有限公司 | 2024-01-05 | — | — | CN | claimed |
| WO-2023001045-A9 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海椿安生物医药科技有限公司 | 2023-10-26 | — | — | WO | claimed |
| WO-2023001045-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海椿安生物医药科技有限公司 | 2023-01-26 | — | — | WO | claimed |
| US-20250304667-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250241921-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| US-20250241922-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| US-12290519-B2 | Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2025-05-06 | — | — | US | disclosed |
| CN-114716544-B | Complement component C5 antibodies | 阿勒根公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240294652-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN K-A, INC. | 2024-09-05 | — | — | US | disclosed |
| WO-1993005039-A1 | 5-HYDROXY-2-PYRIMIDINYLMETHYLENE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-03-18 | — | — | WO | disclosed |
| WO-1992013844-A1 | SUBSTITUTED 4,6-DI-TERTIARY-BUTYL-5-HYDROXY-PYRIMIDINES | WARNER-LAMBERT COMPANY (US) | 1992-08-20 | — | — | WO | disclosed |
| WO-1992013536-A1 | 2-SUBSTITUTED-4,6-DI-TERTIARY-BUTYL-5-HYDROXY-1,3-PYRIMIDINES USEFUL AS ANTIINFLAMMATORY AGENTS | WARNER-LAMBERT COMPANY (US) | 1992-08-20 | — | — | WO | disclosed |
| US-5114958-A | Lipoxygenase or cyclooxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 1992-05-19 | — | — | US | disclosed |
| US-4797483-A | Process for obtaining 4-hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide | INDUSPOL, S.A. (ES) | 1989-01-10 | — | — | US | disclosed |
| EP-0284514-A1 | Process for obtaining 4-hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide | ESTEVE QUIMICA, S.A. (ES) | 1988-09-28 | — | — | EP | disclosed |
| US-4474956-A | Process for the preparation of 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1984-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250241921-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JAK1, TNF, CYP4A11 | KDM4E 1850/4885CA12 2912/4885USP2 2042/4885 |
| US-12290519-B2 | Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof | JAK1, TNF, CYP4A11 | KDM4E 1850/4885CA12 2912/4885USP2 2042/4885 |
| US-20250241922-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JAK1, TNF, CYP4A11 | KDM4E 1850/4885CA12 2912/4885USP2 2042/4885 |
| US-20240197741-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | TNF, CYP4A11, JAK1 | KDM4E 1255/4885CA12 2696/4885USP2 1342/4885 |
| US-20240294652-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | IL17A, IL23R, IL15RA | KDM4E 4708/4885CA12 3675/4885USP2 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.